Not Signed In - Final Data From Phase III Study Show Single-Agent Alemtuzumab (Campath(R), MabCampath(R)) Superior To Chlorambucil For Patients With Untreated B-CLL
Tue, 12 Dec 2006 08:00 AM EST
... Patients with B-cell chronic lymphocytic leukemia (B-CLL) may soon have a more effective treatment option earlier in the course of their disease, according to final data from the CAM 307 international Phase III study presented today at the 48th Annual Meeting of the American Society of Hematology. [click link for full article] ...
Related Topics
- Alemtuzumab
- Data & Statistics
- Agent Orange
- Chemical Agents
- Data Analysis
- National Data
- Antithrombin III
- Chlorambucil
- Mining
- Familial Dysautonomia
- Superior Vena Cava Syndrome
- Migration
- Travel Destinations
- Increased risk of heart attack from untreated diabetes and high cholesterol
- Cll
- Damage to the eyes, kidneys, and nerves due to untreated high blood sugar
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Chronic lymphocytic leukemia (CLL)
- Riot Control Agents
email this page
print this page
bookmark this page
feedback on this page
